GNMSF (Genmab AS) Inventories, Finished Goods: $0 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

GNMSF Genmab AS GNMSF
93 GF Score
Price $285.85
GF Value $347.34
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Inventories, Finished Goods?

Genmab AS GNMSF 93 Inventories, Finished Goods is $0 Mil as of Mar. 2026. GuruFocus rates GNMSF with a GF Score™ of 93/100 and a GF Value™ of $347.34 (Modestly Undervalued). The stock has 5 warning signs investors should review.

Genmab AS's quarterly finished goods increased from Sep. 2025 ($0 Mil) to Dec. 2025 ($13 Mil) but then declined from Dec. 2025 ($13 Mil) to Mar. 2026 ($0 Mil).

Genmab AS's annual finished goods increased from Dec. 2023 ($9 Mil) to Dec. 2024 ($11 Mil) and increased from Dec. 2024 ($11 Mil) to Dec. 2025 ($13 Mil).

Genmab AS Inventories, Finished Goods Historical Data

* Premium members only.

The historical data trend for Genmab AS's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Inventories, Finished Goods Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Finished Goods
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 9.00 11.00 13.00

Genmab AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Finished Goods Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 13.00 0.00
GNMSF
93GF Score
Genmab AS GNMSF
Inventories, Finished Goods is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

What does a Inventories, Finished Goods of $0 Mil mean?
Genmab AS (GNMSF) has a Inventories, Finished Goods of $0 Mil as of Mar. 2026. Finished goods are inventory items that are complete and ready to be sold. View historical data on Genmab AS and its competitors.
Is Genmab AS's Inventories, Finished Goods too high?
Genmab AS's current Inventories, Finished Goods is $0 Mil. Overall, Genmab AS has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Genmab AS's Inventories, Finished Goods compare to VRTX and REGN?
Genmab AS's Inventories, Finished Goods of $0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Finished Goods for a Biotechnology company?
A good Inventories, Finished Goods depends on the Biotechnology industry context. However, Inventories, Finished Goods should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Finished Goods mean?
A high Inventories, Finished Goods can signal that a stock is expensive relative to its fundamentals. Finished goods are inventory items that are complete and ready to be sold. View historical data on Genmab AS and its competitors. Genmab AS's current Inventories, Finished Goods is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genmab AS stock overvalued right now?
Based on GuruFocus' analysis, Genmab AS (GNMSF) is currently considered Modestly Undervalued. The stock's GF Value™ is $347.34, compared to a current price of $285.85 — trading 17.7% below its estimated fair value. The current Inventories, Finished Goods is $0 Mil. Genmab AS's overall GF Score™ is 93/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Finished Goods calculated?
Inventories, Finished Goods is calculated from a company's financial statements. For Genmab AS (GNMSF), the current Inventories, Finished Goods is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Genmab AS (GNMSF) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of $285.85 is trading 17.7% below its estimated GF Value™ of $347.34. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for GNMSF:

  • Inventories, Finished Goods: $0 Mil
  • GF Value™: $347.34 vs. price of $285.85 (17.7% below fair value)
  • GF Score™: 93/100 with 5 warning signs

No single metric tells the full story. See the GNMSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
93GF Score

Get the complete analysis for GNMSF

Inventories, Finished Goods is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$285.85
Price
$347.34
GF Value